Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong Angela DeMichele?

Angela M. DeMichele

Physician

University of Pennsylvania

HQ Phone:  (215) 898-5000

Direct Phone: (215) ***-****direct phone

Email: a***@***.edu

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

University of Pennsylvania

3400 Chestnut St

Philadelphia, Pennsylvania,19104

United States

Company Description

The University of Pennsylvania School of Nursing is one of the world's leading schools of nursing. For the second year in a row, it is ranked the #1 nursing school in the world by QS University, and has four graduate programs ranked number one by U.S. News & W... more.

Find other employees at this company (69,241)

Background Information

Employment History

Associate Editor

BioMed Central Ltd


Assistant Professor, Medicine and Epidemiology

Cancer


Position In Breast Cancer Program

Abramson Cancer Center


Affiliations

Expedition Inspiration

Chair of the Medical Advisory Board


American Board of Internal Medicine

Board Member


Living Beyond Breast Cancer

Member of Medical Advisory Board


LBBC

Member of Medical Advisory Board


Mac Publishing LLC

Board Member


Journal of Clinical Oncology

Member, Editorial Board


EI

Chair of the Medical Advisory Board


Education

B.S.

Biochemistry

Brown University


M.S.C.E.


MD


MD

University of Pennsylvania


MD

University of Pennsylvania , Philadelphia


MD

University of Pennsylvania Perelman School of Medicine


MD

Washington University


MSCE


MSCE degree

University of Pennsylvania SOM


Masters Degree

Clinical Epidemiology

University of Pennsylvania


Web References(82 Total References)


www.targetedonc.com

Angela DeMichele, MD
Angela DeMichele, MD The combination of T-DM1 (ado-trastuzumab emtansine; Kadcyla) and pertuzumab was superior to the combination of paclitaxel and trastuzumab as neoadjuvant treatment for women with HER2-positive breast cancer, according to an analysis the adaptively randomized I-SPY 2 Trial. The goal of the I-SPY 2 trial was to identify drugs and combinations of drugs to further explore in phase III trials. A drug or combination "graduates" by reaching a threshold predictive probability of success in a subsequent phase III trial. Based on the findings from the study, the T-DM1 combination should now advance into a phase III study, said Angela M. DeMichele, MD, at the 2016 AACR Annual Meeting. The toxicity profiles favored the T-DM1/pertuzumab combination versus paclitaxel/trastuzumab, with hypertension, neuropathy, and alopecia occurring much less frequently in patients assigned to T-DM1/pertuzumab. "I would argue that these are side effects of treatment that really matter to women, that can really affect their day-to-day function," said DeMichele, professor of medicine and epidemiology, University of Pennsylvania, Philadelphia. "That led to a probability that T-DM1/pertuzumab was superior to [paclitaxel/trastuzumab] of 99.5%, and our probability that it would be successful in a subsequent phase III trial of 94%," said DeMichele. As expected, elevations of alanine aminotransferase and aspartate aminotransferase levels occurred in patients randomized to T-DM1/pertuzumab "but was low grade, and not clinically signi cant," said DeMichele. "There are numerous phase III trials that are going on now to help establish the role of T-DM1 with or without pertuzumab in the neoadjuvant setting, and we anxiously await those results," she said.


tatcongress.org [cached]

Angela DeMichele, University of Pennsylvania, Philadelphia, PA


www.expeditioninspiration.org [cached]

Angela DeMichele, MD, MSCE
Angela DeMichele, MD, MSCE, has been our Expedition Inspiration Medical Advisory Committee chair since 2009 and became involved with Expedition Inspiration in 2003. Dr. DeMichele is an Associate Professor of Medicine and Epidemiology at the University of Pennsylvania and Senior Scholar in the Center for Clinical Epidemiology and Biostatistics. She co-leads the Breast Cancer Research Program of the Abramson Cancer Center and directs the Doris Duke Clinical Research Fellowship Program at the University of Pennsylvania. Dr. DeMichele earned a B.S. in Biochemistry from Brown University, an M.D. from Washington University School of Medicine (as a Four Schools Physician/Scientist Scholar) and a Masters Degree in Clinical Epidemiology from the University of Pennsylvania. She received her clinical training in Internal Medicine and Hematology/Oncology at the University of Pennsylvania, and joined the faculty in 2000 as a breast cancer oncologist and molecular epidemiologist whose research focuses on identifying markers of outcome, response to therapy and development of targeted therapeutics. She is currently the PI of numerous clinical trials and epidemiologic studies, including Chair of Trial Operations for the I-SPY2 Trial, a multicenter clinical trial in which targeted therapeutics are tested in the context of molecular and MRI imaging response profiles in patients receiving neoadjuvant therapy for locally-advanced breast cancer, and her work has been funded through the NCI and other charitable foundations. In addition, she directs Penn's Breast Cancer Survivorship Program, a multidisciplinary clinical research program at the Abramson Cancer Center, where she and her colleagues are performing studies of bone loss, ovarian dysfunction, hot flashes, lymphedema, depression/distress and physical activity in breast cancer survivors. She is a past recipient of a Young Investigator Award from the American Society of Clinical Oncology, a Clinical Research Training Grant from the American Cancer Society and a Patient-Oriented Career Development Award from the NIH. Dr. DeMichele has served on the American Board of Internal Medicine Oncology Subspecialty Board, the Editorial Board of the Journal of Clinical Oncology and is currently Chair of the Medical Advisory Board of the Expedition Inspiration Fund for Breast Cancer Research. + Expand


fastercures.tumblr.com [cached]

Angela DeMichele of the University of Pennsylvania and co-director of ISPY-2 highlighted the research done through the I-SPY trial which is "interrogating multiple drugs from different companies simultaneously using the same master protocol, cutting the time and cost of development by two thirds.
DeMichele further explained that this adaptive clinical trial design allowed the FDA, industry and academia to come together to "build the infrastructure to test multiple drugs at the same time, matching patients and their tumors to the right drugs. The biggest challenge, she says, is to sustain these efforts and keep it running. However, DeMichele cautioned that "leading and running a consortia is not a skill set that most go into research knowing.


www.cureus.com [cached]

Angela DeMichele
Angela DeMichele M.D. Internal Medicine Breast Cancer Research and Epidemiology University of Pennsylvania School of Medicine Dr. DeMichele is an Associate Professor of Medicine and Epidemiology at the University of Pennsylvania and Senior Scholar in the Center for Clinical Epidemiology and Biostatistics. She co-leads the Breast Cancer Research Program of the Abramson Cancer Center and directs the Doris Duke Clinical Research Fellowship Program at the University of Pennsylvania. Dr. DeMichele earned a B.S. in Biochemistry from Brown University, an M.D. from Washington University School of Medicine (as a Four Schools Physician/Scientist Scholar) and a Masters Degree in Clinical Epidemiology from the University of Pennsylvania. She received her clinical training in Internal Medicine and Hematology/Oncology at the University of Pennsylvania, and joined the faculty in 2000 as a breast cancer oncologist and molecular epidemiologist whose research focuses on identifying markers of outcome, response to therapy and development of targeted therapeutics. She is currently the PI of numerous clinical trials and epidemiologic studies, including Chair of Trial Operations for the I-SPY2 Trial, a multicenter clinical trial in which targeted therapeutics are tested in the context of molecular and MRI imaging response profiles in patients receiving neoadjuvant therapy for locally-advanced breast cancer, and her work has been funded through the NCI and other charitable foundations. In addition, she directs Penn's Breast Cancer Survivorship Program, a multidisciplinary clinical research program at the Abramson Cancer Center, where she and her colleagues are performing studies of bone loss, ovarian dysfunction, hot flashes, lymphedema, depression/distress and physical activity in breast cancer survivors. She is a past recipient of a Young Investigator Award from the American Society of Clinical Oncology, a Clinical Research Training Grant from the American Cancer Society and a Patient-Oriented Career Development Award from the NIH. Dr. DeMichele has served on the American Board of Internal Medicine Oncology Subspecialty Board, the Editorial Board of the Journal of Clinical Oncology and is currently Chair of the Medical Advisory Board of the Expedition Inspiration Fund for Breast Cancer Research.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory